Which cancers are associated with Cowden syndrome?

[Anonymous]

Which cancers are associated with Cowden syndrome?

[Genetic Counselor]

Cowden syndrome is linked to an increased risk of several cancers. It is part of PTEN hamartoma tumor syndrome (PHTS), which can involve increased risks of breast, thyroid, endometrial, kidney, and colorectal cancer. Some studies also suggest a possible increase in melanoma risk. These are increased risks, not certainties: having a PTEN variant does not mean a person will develop cancer.
For women with PHTS, breast cancer is a major concern. Published estimates differ because studies have included different groups of patients and used different methods. One analysis that accounted for study bias estimated a risk of roughly 54% to 76% by age 60. Those figures describe groups, not an individual’s exact likelihood. Personal and family history, age, and other factors can affect a person’s risk assessment.

Thyroid cancer risk is also elevated. Follicular thyroid cancer is more common in PHTS than it is in the general population, although other types can occur. People may also develop benign thyroid nodules or goiter. Because thyroid changes can be benign or malignant, any monitoring plan should be based on medical guidance rather than on symptoms alone.
Endometrial cancer affects the lining of the uterus. People should know to report symptoms such as unexpected or abnormal vaginal bleeding promptly. Routine screening approaches are not identical across guidelines, so a clinician can explain whether any monitoring is appropriate for a particular person.

There are increased risks of kidney and colorectal cancer as well. Colorectal polyps can occur in PHTS, and colonoscopy may be recommended to assess polyps and detect concerning changes. Kidney imaging may also be considered as part of a surveillance plan. Skin examinations may be useful because melanoma risk may be increased.

These risks are why care often includes a tailored screening schedule and education about symptoms that warrant medical assessment. Recommendations can differ by guideline, age, sex, medical history, and family history. For example, if a close relative developed a related cancer at a young age, a clinician may consider starting certain screening earlier.

A clinical geneticist, genetic counselor, or specialist team can explain which risks apply and how current guidance fits the person’s situation. Avoid treating a single lifetime-risk number as a prediction for an individual; it is a planning tool, not a diagnosis or forecast.

[Author]

Posts